

following anti-core monoclonal antibodies may also be utilized for purposes of the present invention: 107-35-54, 110-81-17, 13-975-157, 14-1350-210 (see U.S. Patent No. 5,753,430) and Toner HCV core monoclonals C11-3, 7, 10, 14 and 15 (see PCT Application WO 099/06836), all of which are available from the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209. (For a discussion of the manner in which monoclonal antibodies may be created, see Kohler and Milstein, Nature (1975) 256:494, and reviewed in Monoclonal Hybridoma Antibodies: Techniques and Applications, ed. Hurrell (CRC Press, Inc., 1982); see also J.W. Goding in *Monoclonal Antibodies: Principles and Practice* (Academic Press, N.Y., 1983; see also U.S. Patent No. 5,753,430).

B1  
omitted.

Ex. note → Page 18, line 15 - line 36, please replace Table I with the following:

TABLE I  
HCV-Core Derived Peptides

<u>Peptide</u>	<u>Sequence</u>	<u>Core Reg. Repr.</u>
A	MSTNPKPQKKNKRNTNRR (SEQ ID NO:46)	1-18
B	NKRNTNRRPQDVKFPGGG (SEQ ID NO:47)	11-28
C	DVKFPGGGQIVGGVYLLP (SEQ ID NO:48)	21-38
D	VGGVYLLPRRGPRLGVRA (SEQ ID NO:49)	31-48
E	GPRLGVRATRKTSEERSQP (SEQ ID NO:50)	41-58
F	KTSEERSQPRGRRQPIPKA (SEQ ID NO:51)	51-68
G	RRQPIPKARRPEGRTWAQ (SEQ ID NO:52)	61-78
H	PEGRTWAQPGYPWPLYGN (SEQ ID NO:53)	71-88
I	QYPWPLYGNEGCGWAGWLL (SEQ ID NO:54)	81-98
J	CGWAGWLLSPRGRSPSW (SEQ ID NO:55)	91-107
1	WLLSPRGRSPSWGPTDPRRRSRNLG (SEQ ID NO:56)	96-120
2	SWGPTDPRRRSRNLGKVIDTLTCGF (SEQ ID NO:57)	106-130
3	SRNLGKVIDTLTCGFADLMGYIPLV (SEQ ID NO:58)	116-140
4	LTCGFADLMGYIPLVGAPLGAARA (SEQ ID NO:59)	126-150
5	YIPLVGAPLGAARALAHGVRVLED (SEQ ID NO:60)	136-160
6	GAARALAHGVRVLEDGVNYATGNLP (SEQ ID NO:61)	146-170
7	LEDGVNYATGNLPGCSFSIFLLA (SEQ ID NO:62)	158-180
8	LPGCSFSIFLLALLSCLTVPASA (SEQ ID NO:63)	169-191

B2